Drug Profile
Glucagon-like peptide-1 oral transmucosal - Watson
Latest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Watson Laboratories
- Class Glucagon-like peptides
- Mechanism of Action Glucagon like peptide 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 14 May 2003 Watson Laboratories is seeking a partner to develop and commercialise the product worldwide (http://www.watsonpharm.com)
- 14 May 2003 No development reported - Phase-I for Type-2 diabetes mellitus in USA (Transmucosal)
- 16 Jan 2001 TheraTech is now called Watson Laboratories